99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label single photon emission computed tomography / computed tomography
(SPECT/CT) study to investigate the safety and diagnostic performance of
99mTc-HYNIC-3PEG4-E[c(RGDfK)2) (99mTc-3PRGD2) in esophagus cancer patients. A single dose of
nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 ( ≤ 20 µg 3PRGD2) will be intravenously
injected into the patients in suspicion of esophagus cancer. Visual and semiquantitative
method will be used to assess the whole-body planar and thoracic SPECT/CT images. Any adverse
events will be collected from the patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University